Bristol-Myers Squibb and LabCentral team up in Cambridge, Massachusetts to support promising biotech startup companies

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, today announced an agreement in which Bristol-Myers Squibb has become a LabCentral platinum sponsor. As part of the agreement, Bristol-Myers Squibb can nominate up to two innovative life-sciences and biotech startup companies per year to take up residence in LabCentral’s Kendall Square facilities. The 2016 nomination process for Bristol-Myers Squibb-sponsored Golden Tickets will launch by the end of the first quarter.

"We are thrilled to welcome Bristol-Myers Squibb to Kendall Square and excited to have it join LabCentral's growing roster of global-company sponsors," said LabCentral co-founder and president, Johannes Fruehauf, M.D., Ph.D. "Clearly, the LabCentral model - providing functional units of space and creating a supportive environment for nascent companies - is meeting a resounding need in the marketplace. Our residents who are working to move early-stage science from the lab bench toward clinical trials stand to gain valuable insights from regular interactions with Bristol-Myers Squibb mentors who are veterans of the process. But we believe it's a symbiotic relationship; this partnership will enable Bristol-Myers Squibb to benefit from proximity and better access to our entrepreneurs as well as LabCentral alumni and others working in some of the region’s most exciting life-sciences startups."

"Bristol-Myers Squibb is excited to partner with LabCentral, which serves as a launch pad for scientific innovation, as it naturally aligns with our focus on accelerating the discovery and development of potentially transformational medicines for patients with serious diseases," said Carl Decicco, Ph. D., Head of Discovery at Bristol-Myers Squibb. "This sponsorship also builds on our growing commitment to the Cambridge community, one of the most vibrant ecosystems of world class science, innovation and entrepreneurship."

In June 2015, Bristol-Myers Squibb announced that it will open a new state-of the-art research site in Cambridge, Mass. The new facility will be located at 100 Binney Street in Kendall Square and is expected to open in early 2018.

Regarding Golden Tickets, Dr. Fruehauf said, "Collaboration is also a fundamental tenet underlying the LabCentral Golden Ticket program. A Golden Ticket represents one underwritten bench space per year for one scientist at LabCentral and a priority spot on the waiting list - invaluable for an early-stage company with limited resources. However, equally important is the close bonds that are formed between fledgling start-up and sponsor; the program provides sponsors with important early access to potentially transformational targets and technology. Anecdotally, I also hear that the enthusiasm of our entrepreneurs and the cross-fertilization of science and ideas that takes place at LabCentral energizes sponsors to bring some of that 'start-up spirit' back to their regular workplace." Dr. Fruehauf added, "We look forward to a fruitful, long-term alliance with Bristol-Myers Squibb."

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About LabCentral
A 28,000 square-foot facility in the heart of the Kendall Square, Cambridge, Mass., a biotech innovation hub, LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups. It offers fully permitted laboratory and office space for early-stage companies comprising approximately 125 scientists and entrepreneurs. LabCentral provides first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series - as well as the other critical services and support that startups need to begin laboratory operations on day one. A private, nonprofit institution, LabCentral was funded in part by a $5 million grant from the Massachusetts Life Sciences Center, with support from its real-estate partner, MIT. Founding sponsors include Triumvirate Environmental and Johnson & Johnson Innovation.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ …

The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018. Nine of the pos...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...